DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20195789

Cefixime and ornidazole combination induced fixed drug eruption: a case report

Sakthibalan Murugesan, Gerard Marshall Raj, Mangaiarkkarasi Adhimoolam

Abstract


Cefixime, a third generation cephalosporin and ornidazole, a nitroimidazole is used for a wide variety of conditions like urinary tract infections, otitis media, pharyngitis, uncomplicated gonorrhea and anaerobic infections. Fixed drug eruption (FDE) is commonly associated with anticonvulsants, antimicrobials and NSAIDs. Here we report a case of a rare cefixime and ornidazole combination induced fixed drug eruption. A 39 year old male developed hyper-pigmented patches over both forearms and left thigh after consuming fixed dose combination of cefixime and ornidazole tablet for the treatment of urinary tract infection.


Keywords


Cefixime, Ornidazole, fixed dose combination, Fixed drug eruption, Hyper-pigmented patches

Full Text:

PDF

References


Kavoussi H, Rezaei M, Derakhshandeh K, Moradi A, Ebrahimi A, Rashidian H, et al. Clinical Features and Drug Characteristics of Patients with Generalized Fixed Drug Eruption in the West of Iran (2005-2014). Dermatol Res Pract. 2015;2015:236703.

Saini R, Sharma B, Verma PK, Rani S, Bhutani G. Fixed drug eruptions: causing drugs, pattern of distribution and causality assessment in a leading tertiary care hospital. Int J Res Med Sci 2016;4(10):4356-8.

MacDougall A. Penicillins, Cephalosporins, and Other β-Lactam Antibiotics, The Pharmacological Basics of Therapeutics: 13th edition, Goodman & Gilman, McGraw Hill; 1989: 1023-1028.

Naranjo CA, Busto U, Sellars EM,Sandor P, Ruiz I, Roberts EA and Janecek E. Method for Estimating theProbability of Adverse DrugReactions. Clin Pharmacol Ther. 1981;30:239-45.

The use of the WHO-UMC system for standardised case causality assessment. Accessed from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed on 5th July 2019.

Hartwig SC, Siegel J and Schneider PJ. Preventability and Severity Assessment in Reporting AdverseDrug reactions. Am J Hospital Pharma. 1992;49:2229-31.

Greaves MW. Antihistamines. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders, Elsevier; 2007: 391-400.

Sehgal VN, Verma P, Bhattacharya SN. Cutaneous tuberculosis: a diagnostic dilemma. Skinmed. 2012;10(6):373-83.

Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002;161:1337-47.

Hiatt KM, Horn TD. Cutaneous toxicities of drugs. In: Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X, editors. Levers Histopathology of the Skin. 10th ed. New Delhi: Lippincott Williams and Wilkins; 2009. pp. 311-31

Pai VV, Bhandari P, Kikkeri NN, Athanikar SB, Sori T Indian J Pharmacol. 2012;44(5):643-5.

Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65(5):795-6.

Wirtz VJ, Mol PG, Verdijk J, Vander Stichele RH, Taxis K. Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. Trop Med Int Health. 2013;18(4):416-25.

McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. PLoS Med. 2015;12(5):e1001826.

McGettigan P, Roderick P, Kadam A, Pollock AM. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019;85:59-70.

Shafi QN, Kumar G, Gautam V, Ray P, Malhotra S. Fixed-dose combinations of antimicrobials: a need for special attention. Indian J Med Microbiol. 2016;34:208-9.

Gupta R. Fixed drug eruption due to ornidazole. Indian J Dermatol. 2014;59(6):635-5.

Choudhury D, Chakravarty P. Fixed Drug Eruption Due to Ornidazole- A Case Report. Sch J App Med Sci. 2016;4(4B):1183-6.

Celik IK, Buyuktiryaki B, Misirlioglu ED, Hasbek E, Kocabas CN. Fixed drug eruption related to cefixime in an adolescent case. J Allergy Clin Immunol Pract. 2018;6(5):1742-3.

Manchukonda RS, Ramakrishna M. Ofloxacin/ornidazole induced fixed drug eruptions: a case report. Int J Basic Clin Pharmacol. 2016;5(2):534-8.

Varma SK, Nagpure S, Misra AK, Dhanvijay P. Fixed drug eruption due to fixed dose combination: A novel case. Int J Health Allied Sci 2013;2(2):130-2.